E Fund Management Co. Ltd. Increases Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

E Fund Management Co. Ltd. raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 47.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,580 shares of the company’s stock after buying an additional 6,986 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $466,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Syndax Pharmaceuticals by 13.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 577,022 shares of the company’s stock valued at $12,469,000 after acquiring an additional 70,555 shares during the last quarter. MeadowBrook Investment Advisors LLC purchased a new position in Syndax Pharmaceuticals during the fourth quarter worth about $37,000. Swiss National Bank boosted its holdings in Syndax Pharmaceuticals by 17.7% in the 4th quarter. Swiss National Bank now owns 142,400 shares of the company’s stock valued at $3,077,000 after purchasing an additional 21,400 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in shares of Syndax Pharmaceuticals by 20.1% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 159,803 shares of the company’s stock valued at $3,453,000 after buying an additional 26,769 shares during the period. Finally, CWM LLC grew its position in Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after acquiring an additional 1,358 shares during the period.

Analysts Set New Price Targets

A number of research firms have commented on SNDX. HC Wainwright restated a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Friday, April 26th. JPMorgan Chase & Co. boosted their price objective on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Finally, Scotiabank cut shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their price target for the company from $36.00 to $23.00 in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock traded down $0.80 during trading hours on Wednesday, reaching $22.38. 1,105,810 shares of the company were exchanged, compared to its average volume of 1,119,221. The firm has a market cap of $1.90 billion, a PE ratio of -7.56 and a beta of 1.01. The stock’s fifty day moving average is $22.47 and its 200 day moving average is $20.16. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period in the prior year, the firm posted ($0.62) earnings per share. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.74 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).